

Original Article

Pravastatin and Olmesartan Synergistically Ameliorate Renal Failure-Induced Vascular Calcification

Katsuya Iijima^{1,2}, Yuki Ito², Bo-Kyung Son², Masahiro Akishita² and Yasuyoshi Ouchi^{2,3}

¹Institute of Gerontology, The University of Tokyo, Tokyo, Japan

²Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

³Federation of National Public Service Personnel Mutual Aid Associations Toranomom Hospital, Tokyo, Japan

Aim: Vascular calcification is a critical problem in patients with chronic kidney disease (CKD). In this study, we examined the effects of a HMG Co-A reductase inhibitor (statin) and an angiotensin II type 1 receptor blocker (ARB) on renal failure-induced vascular calcification.

Method and Result: Severe renal failure was induced in rats by feeding a 0.75% adenine diet for six weeks. These rats had hyperphosphatemia, hypertension and hypercholesterolemia. A histological assessment showed extensive linear calcification in the aortic media and a significant increase in the aortic content of calcium and phosphorus. Oral administration of pravastatin (a statin; 1-10 mg/kg/day) or olmesartan (an ARB; 1-10 mg/kg/day) dose-dependently inhibited the aortic calcification in parallel with their renoprotective, lipid-lowering and blood pressure-lowering effects. Of note, the lowest dose of pravastatin inhibited aortic calcification with no influence on the renal function, BP and cholesterol, suggesting that it has direct vasoprotective properties. Intriguingly, the combined administration of pravastatin and olmesartan at the lowest doses synergistically ameliorated the aortic calcification, and the protective effect was at least partly attributable to the inhibition of RF-induced apoptosis in the aortic wall. An *in vitro* model of inorganic phosphate (Pi)-induced vascular smooth muscle cell calcification mimicked these effects of pravastatin and olmesartan, and the beneficial effect of the combination was attributable to the inhibitory effects on Pi-induced apoptosis via the restoration of the Gas6/Axl-mediated anti-apoptotic pathway.

Conclusion: A statin and an ARB exerted potent protective effects against vascular calcification due to CKD, probably through their pleiotropic effects. In addition, combination therapy with pravastatin and olmesartan may provide a new therapeutic strategy for the prevention of vascular calcification.

J Atheroscler Thromb, 2014; 21:917-929.

Key words: Vascular calcification, Chronic kidney disease, Statin, ARB, Combination therapy

Introduction

Vascular calcification is frequently associated with cardiovascular (CV) events and mortality^{1, 2}. It has been shown that the high rates of CV events in patients with chronic kidney disease (CKD) cannot be completely explained by the excess of traditional risk fac-

tors, and these CKD patients have also been shown to possess a disproportionate burden of vascular calcification with several unique clinical findings, such as isolated systolic hypertension and orthostatic hypotension³. Therefore, the inhibition of vascular calcification is essential for preventing CV events in these patients, and would lead to more stable hemodynamics. In general, vascular calcification occurs at two anatomical sites in the vessel wall, the arterial media and the intima. The medial calcification frequently seen in CKD patients on dialysis as inappropriate biomineralization is observed as continuous linear deposits along the internal elastic lamina, in contrast to the intimal

Address for correspondence: Katsuya Iijima, Institute of Gerontology, The University of Tokyo. 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656 Japan

E-mail: katsu-tky@umin.ac.jp

Received: December 28, 2013

Accepted for publication: April 2, 2014

calcification seen as patchy scattered deposits occurring only within atherosclerotic plaques^{4, 5}).

Recent evidence has shown that vascular calcification is attributable to an active cell-mediated process resembling osteogenesis in bone, rather than passive mineral precipitation^{6, 7}, because the expression of bone-associated proteins, such as osteopontin, matrix Gla protein and the bone-specific transcription factor, Runx2/Cbfa-1, was found in the calcified medial area⁸. The mechanism responsible for the vascular calcification has been thought to be due to the induction of osteoblastic phenotypic changes, which result from an imbalance in the serum calcium and phosphorus levels in vascular smooth muscle cells (VSMC)⁹. Although hyperphosphatemia, which is frequently seen in patients with severe CKD, has been shown to be associated with the development of vascular calcification, the precise mechanisms underlying the development of vascular calcification in CKD have not been fully elucidated.

It is well known that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors (statins) and angiotensin II type 1 receptor blockers (ARBs) have potent anti-atherogenic effects via not only lipid-lowering and/or blood pressure (BP)-lowering effects, but also their unique properties that are independent of these effects^{10, 11}. In addition, the synergistic beneficial effects of combination therapy with both types of drugs on BP control have been reported¹². We also previously reported that several statins protected against the calcification of cultured VSMCs by inhibiting apoptosis as an initial step of nucleation¹³. However, thus far, the effects of statins and ARBs on vascular calcification have not been fully evaluated in *in vivo* and clinical studies.

Aim

Further pathophysiological understanding is necessary to design effective therapeutic strategies against the vascular calcification in CKD; therefore, it is of interest to identify new preventive therapies that can abrogate vascular calcification. In this study, we examined whether a statin or ARB could prevent aortic calcification in a rat model of severe renal failure. In addition, we hypothesized that the additive inhibitory effects of combination therapy might be more effective than the effects of either single therapy on the renal failure-induced aortic calcification.

Methods

Experimental Renal Failure Rats

Renal failure was induced by feeding rats a 0.75% adenine-containing diet as described previously¹⁴. In brief, 12-week-old male Wistar rats (Nippon Clea Inc., Tokyo, Japan) were pair-fed standard CE-2 chow (containing 1.2% calcium and 0.6% phosphorus; Nippon Clea Inc.) in the control group or CE-2 chow containing 0.75% adenine (Sigma) in the renal failure group for six weeks. The diet was then returned to normal chow, and the rats were fed the normal diet for an additional two weeks. The adenine-fed rats were given oral pravastatin (1-10 mg/kg/day; Daiichi Sankyo Co., Ltd., Tokyo, Japan), olmesartan (1-10 mg/kg/day; Daiichi Sankyo Co., Ltd.) or both pravastatin (1 mg/kg/day) and olmesartan (1 mg/kg/day), in their drinking water throughout the eight weeks of the experiments ($n=10$ in each group). In preliminary experiments, one rat each with and without renal failure was sacrificed every two weeks, and the BP and biochemical parameters were measured. The food and water consumption were regularly checked every three days, and the total volume of drug administration was adjusted over the whole period. All procedures and animal care were performed in accordance with the Guide for the Care and Use of Laboratory Animals of the University of Tokyo.

Measurement of the Blood Pressure and Biochemical Parameters

The blood pressure (BP) and heart rate were measured in conscious rats by tail-cuff plethysmography (BP-98A, Softron Co, Tokyo, Japan) every two weeks. To measure the biochemical parameters, such as the renal function, lipid profile and mineral metabolism, blood samples were collected by cardiac puncture under diethyl ether anesthesia. The serum levels of creatinine (Cre), calcium (Ca), inorganic phosphorus (P), total cholesterol (T-chol) and triglycerides (TG) were measured with an autoanalyzer (Hitachi-7180, Japan). In addition, urine was collected from each rat simultaneously to measure the excretion of urinary albumin as another parameter of renal damage.

Assessment of Calcification in the Aortic Wall

The aortic calcification induced by renal failure was evaluated using several procedures. In addition, each whole aorta was stained with Alizarin red, which could detect mineralization in a preliminary experiment. In addition, the aortic calcification was also evaluated by ultrasound examination (Agilent Co.

Ltd). As a next step, two different methods were carried out to compare the degree of aortic calcification between the groups.

First, as a histological assessment, the aorta was perfusion-fixed *in situ* with 10% buffered formalin at a constant, non-pulsatile pressure of 100 mmHg. The aortas were embedded in paraffin and sequentially cut into cross-sections with 5- μ m thickness from the ascending aorta to the aortic arch. To detect calcification in the aortic wall, each cross-section was evaluated by von Kossa staining. To compare the extent of calcification in each group, the areas of calcified lesions and the aortic media between the internal and external elastic laminae were measured using a computerized histological analysis system (Scion Image Software), and then the ratio of the calcified area to the area of the aortic media was calculated. The data were collected from each of six sub-serial cross-sections at 100- μ m intervals, and the average was taken as the value of each animal ($n=5$ in each group). This histological analysis was performed in a manner where the investigators were blinded to the treatment groups of the animals.

Second, to quantitate the mineral deposition in the aorta, the content of calcium (Ca) and phosphorus (P) in the carbonized aorta was measured using the *o*-cresolphthalein complexone method (C-Test, WAKO, Tokyo, Japan) after the determination of the weight of the dried aorta ($n=5$ in each group).

Determination of Apoptosis

The level of apoptosis in the aortic wall was detected by a terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay with ApopTag Plus obtained from Chemicon International, Ltd. (Hampshire, UK), according to the manufacturer's instructions. To evaluate the Pi-induced apoptosis in the VSMC, cytoplasmic histone-associated DNA fragments were evaluated with a cell-death detection ELISA kit (Roche, Mannheim, Germany) as a quantitative index of apoptosis.

VSMC Calcification *in Vitro*

To examine the mechanism(s) underlying the vascular calcification in an *in vitro* model, VSMCs were cultured with a statin and/or ARB. Calcification was induced in human aortic smooth muscle cells by treatment with a high dose (2.6 μ mol/L) of inorganic phosphate (Pi; a mixed solution of Na_2HPO_4 and NaH_2PO_4 , pH was adjusted to 7.4) for six days, as described previously¹⁰. The cells were simultaneously treated with pravastatin (50 μ M) or olmesartan (100 μ M) in the presence of 2.6 μ mol/L Pi in the culture

medium. The effect of each drug on the Ca deposition in the cells was determined by the *o*-cresolphthalein complexone method and by von Kossa staining to visualize the mineralization. In addition, to examine the synergistic effects of combined treatment with both drugs on the Ca deposition and the apoptosis-related cascade, the expression of Gas6, Axl and phosphorylated Akt (p-Akt), as a downstream signal of this pathway, was examined on day 6 by a Western blotting/SDS-PAGE analysis using each specific primary antibodies. The experiments were performed with at least three different cell populations.

Statistical Analysis

All results are presented as the means \pm standard error (SE). The differences between the groups were analyzed using an ANOVA, followed by Bonferroni's test. A stepwise (forward) multiple regression analysis was performed to clarify the relationships among the aortic calcification, treatments and other measurements. A value of $p < 0.05$ was considered to be significant.

Results

Aortic Calcification in Renal Failure Rats

After the induction of severe renal failure, calcification in the aorta was markedly observable by the naked eye at eight weeks (Fig. 1A). Ultrasound examinations showed high echoic signals in the aortic wall of the renal failure rats, suggesting the presence of massive calcification. In addition, Alizarin red staining showed significant calcification in the whole aorta (Fig. 1B). Histological assessment using von-Kossa staining demonstrated that the renal failure rats had extensive linear calcification, which was localized in the aortic media (Fig. 1C). Neointimal plaque formation was not found even in the renal failure group (data not shown), thus suggesting that the renal failure rats showed a typical Mönckeberg's sclerosis pattern.

Beneficial Effects of Statin and/or ARB Treatment on the Laboratory Parameters

Continuation of the adenine diet for six weeks induced severe renal failure with hyperphosphatemia and massive albuminuria (Fig. 2). In addition, the adenine-fed rats also showed a significant increase in the BP and serum T-chol. Olmesartan significantly ameliorated the increase in serum Cre in a dose-dependent manner, suggesting that it had renoprotective effects. The beneficial effect of pravastatin was very slight. Similar to the improvement of the serum Cre, the albuminuria was also inhibited by drug inter-




Fig. 1. Extensive aortic calcification in rats with renal failure induced by adenine feeding.

(A) Representative photographs of aortas from control (left) and renal failure (right) rats just after sacrifice. Massive calcification (arrow) was found in the aorta of the renal failure rats. Ultrasound examinations demonstrated high echoic signals in the aortic wall of adenine (AD)-fed rats, suggesting the presence of massive calcification. (B) The mineral deposition in whole aorta of control rat or renal failure rat was visualized by Alizarin red staining. (C) The histopathological assessment of calcification using von Kossa staining showed extensive linear calcification in the aortic media, so-called Mönckeberg's sclerosis.

vention. Especially compared to the pravastatin group, a significant improvement of albuminuria was found in the olmesartan group, which was similar to its preventive effects on the elevation in the serum Cre and the BP. Pravastatin and olmesartan ameliorated hyperphosphatemia by 17% and 35%, respectively. The highest dose of pravastatin (50 mg/kg/day) significantly improved the hypercholesterolemia, although no lipid-lowering effect was found at the lower doses

of pravastatin. Intriguingly, a partial decline in the elevated T-chol level was unexpectedly observed even in rats administered the high dose (10 mg/kg/day) of olmesartan. The elevated BP was dose-dependently attenuated not only by olmesartan, but also by pravastatin. Notably, combined administration of the lowest doses (1 mg/kg/day) of pravastatin and olmesartan led to significant improvement of the renal function (especially albuminuria) and hypertension, and the




Fig. 2. The renoprotective, lipid-lowering and BP-lowering effects of the statin and/or ARB in renal failure rats.

Serum parameters, such as the creatinine (Cre; mg/dL), calcium (Ca; mg/dL), inorganic phosphorus (P; mg/dL), calcium-phosphorus product (CaXP; mg²/dL²) and total-cholesterol (T-chol; mg/dL) level, as well as the systolic blood pressure (sBP; mmHg), were measured at the end of the experiments (eight weeks). The urinary albumin excretion relative to the urinary creatinine excretion (U-Alb/Cre; mg/mg) was also measured at the same time. Pravastatin (PR; 1, 10, 50 mg/kg/day) and olmesartan (OL; 1, 10 mg/kg/day) each dose-dependently showed potent renoprotective effects, including inhibition of albuminuria, and combined administration (PR1 + OL1) demonstrated additive beneficial effects even when both were administered at the lowest doses. Each value indicates the mean ± SE.

*: $p < 0.05$ vs control rats without renal failure and drug administration. †: $p < 0.05$ vs adenine-induced renal failure rats without drug administration. #: $p < 0.05$ vs adenine-induced renal failure rats treated with pravastatin (1 mg/kg/day).

beneficial effects of combination therapy were greater than those of either single therapy.

Synergistic Protection by Combination Therapy

The quantitative measurement of the aortic calcification was performed using two distinct methods, von Kossa staining and determination of the aortic Ca/P content. Pravastatin and olmesartan significantly inhibited aortic calcification in a dose-dependent manner, and the combination of the lowest doses of both drugs inhibited the calcification more effectively than either drug alone (Fig. 3A). A statistical analysis

of the ratio of the calcified area showed synergistic inhibition by the combined administration (Fig. 3B). The quantitative assessment of aortic mineralization showed that the Ca content in the dried aorta was markedly increased ($18.7 \pm 2.2 \mu\text{g}/\text{mg}$, $p < 0.001$) by the adenine diet compared with the control rats ($0.1 \pm 0.1 \mu\text{g}/\text{mg}$) (Fig. 4A), and the aortic P content was also similarly increased (Fig. 4B). Each drug dose-dependently reduced the aortic Ca content, and the maximal reduction was 94% in the highest-dose pravastatin group and 77% in the high-dose olmesartan group, compared with untreated renal failure rats.




Fig. 3. The inhibitory effects of the statin or ARB and their synergistic benefit on renal failure-induced calcification in the aorta.

Two quantitatively distinct assessments of the aortic calcification were carried out. A. The ratio of the calcified area to the aortic media in each section from the ascending aorta to the aortic arch was calculated ($n=5$ each group). Pravastatin (PR; 1, 10 mg/kg/day) and olmesartan (OL; 1, 10 mg/kg/day) each dose-dependently inhibited the aortic calcification. Significant synergistic inhibition by combined administration (PR1 + OL1) was found even at the lowest doses.

The reduction of the aortic P content by drug intervention was comparable to the reduction of the Ca content. These changes in the aortic Ca and P content were consistent with the histological changes detected by von Kossa staining. Notably, partial inhibition of the aortic calcification by pravastatin was found even at the lowest dose, with no change in the serum Cre, T-chol, P or BP. In addition, combined administration of low-dose olmesartan with low-dose pravastatin

additively reduced the elevated Ca/P content in the aorta, and this decrease was markedly higher than that induced by treatment with pravastatin alone. To dissect the renoprotective, BP-lowering and lipid-lowering effects of the statin and ARB, a stepwise multiple regression analysis was performed. The statistical results showed that the use of pravastatin and olmesartan was independently related to the aortic Ca content ($\beta = -0.605$ and -0.398 , respectively, $p < 0.01$), but




Fig. 4. The quantitative comparison of the inhibitory effects of the statin and/or ARB on renal failure-induced calcification in the aorta.

To quantitatively measure the inhibitory effects of pravastatin (PR) and/or olmesartan (OL) on renal failure-induced aortic calcification at eight weeks, the content of calcium (A) and phosphorus (B) in the dried aorta was measured. Pravastatin and olmesartan each dose-dependently and significantly inhibited the aortic Ca and P contents. The combination of pravastatin and olmesartan demonstrated synergistic inhibitory effects on the deposition of both Ca and P in the aorta.

Data are shown as the means \pm SE.

*: $p < 0.01$ vs adenine-induced renal failure rats without drug administration.

#: $p < 0.05$, †: $p < 0.01$. N.D.: not detected.

*: $p < 0.05$ vs adenine (AD)-induced renal failure rats without drug administration. †: $p < 0.05$ vs adenine-induced renal failure rats treated with pravastatin (1 mg/kg/day).

the serum Cre, T-chol, systolic BP and urinary albumin/Cre were not.

Inhibition of Apoptosis in the Aortic Wall

The extent of apoptosis in the aortic wall was evaluated by TUNEL staining (Fig. 5). Massive apoptosis was found in the renal failure rats, and the localization of the fluorescent signal was consistent with the calcified area. Low-dose pravastatin significantly inhibited the cell apoptosis similar to its effects on calcification. Notably, the combined treatment with pravastatin and olmesartan at the lowest dose completely inhibited the apoptosis.

Additive Inhibitory Effects of Combination Treatment on VSMC Calcification *in Vitro*

We have previously shown that the Gas6/Axl-mediated survival pathway plays an essential role in VSMC calcification via Pi-induced apoptosis¹⁰. To further understand the precise mechanism by which both drugs inhibited the aortic calcification induced by renal failure-based hyperphosphatemia, we decided

to perform mechanistic experiments *in vitro* using human aortic smooth muscle cells to assess the inhibitory effects of pravastatin and olmesartan.

As shown in Fig. 6, each drug significantly inhibited the Pi-induced apoptosis and the subsequent Ca deposition in human VSMCs, and this inhibition was additively augmented by the combined treatment. In the assessment of the anti-apoptotic signals, single treatment with each drug significantly restored the downregulated expression of Gas6, Axl and p-Akt by Pi stimulation. The partial restoration of Axl and p-Akt, but not Gas6, was similar to the degree of inhibition of apoptosis and the subsequent calcification. The statistical analysis showed an additive benefit of combined treatment, which was more effective than either single treatment.

Discussion

The present study showed that treatment with a statin and an ARB prevented renal failure-induced aortic calcification, and the combined administration




Fig. 5. The induction of apoptosis in the aortic wall of renal failure rats and the inhibitory effects of combination therapy.

The induction of apoptosis in the aortic wall was assessed by TUNEL staining. (A and B) Apoptosis was strongly induced by renal failure, and the apoptotic findings (right panel) were localized to the calcified area, as detected by von Kossa staining (left panel). (C) The administration of pravastatin at the lowest dose (PR1) showed significant inhibition of not only calcification, but also apoptosis. (D) Treatment with the combination of pravastatin (PR1) and olmesartan (OL1) even at the lowest doses showed complete inhibition of the apoptosis and subsequent calcification.

of both drugs synergistically exerted beneficial effects. The possible mechanisms by which combination therapy can abolish aortic calcification more effectively than each single therapy may include not only renoprotective and antihypertensive effects, but also direct effects of the drugs on the vasculature. Thus far, the clinical effects of statins on calcification of CV system are still controversial, and there are no clinical or basic reports showing the effects of ARBs on vascular calcification. This study explored the efficacy regarding the preventive potential of using a combination of a statin and an ARB against vascular calcification.

The CV-associated mortality in CKD patients on dialysis has been shown to be 10 to 30 times higher than that in the general population¹⁵. In particular, extensive calcification in the arterial media is strongly associated with the increased CV event rates in CKD patients^{16, 17}. In the present study, adenine-fed rats exhibited severe renal failure with massive albuminuria and subsequent hypertension and hypercholesterolemia. A histopathological assessment of the kidneys showed progressive proximal tubular dilation and atrophic glomeruli (data not shown), similar to a previous report¹⁴. The renal failure rats showed extensive

linear calcification in the media of the aortic wall, resembling the typical Mönckeberg's pattern frequently seen in CKD patients.

Inhibitory Effects of the Statin

With respect to the clinical efficacy of statins for CV calcification, several retrospective studies have demonstrated inhibitory effects on calcific changes in the aortic valve^{18, 19} and coronary arteries^{20, 21}. However, a recent prospective study did not show significant inhibitory effects²². Therefore, it is currently unclear whether statins directly affect the genesis of vascular calcification in the clinical setting, including in patients with CKD. In this study, renal failure-induced aortic calcification was significantly inhibited by pravastatin in a dose-dependent manner. Pravastatin administration showed strong renal protection and a dose-dependent reduction in the blood pressure and serum cholesterol level, suggesting that the blood pressure reduction might be a consequence of the improvement of renal function by pravastatin.

Especially in CKD patients, recent reports have shown cardioprotective effects²³ (an improvement in flow-mediated vasodilation) and renoprotective




Fig. 6. The synergistic inhibitory effects of the statin and ARB on the phosphate-induced VSMC apoptosis and subsequent calcification.

Human VSMCs were treated with or without high-dose (2.6 µM) inorganic phosphate (Pi) for six days. Pi stimulation significantly increased the apoptosis and the subsequent Ca deposition, as shown. To assess the Gas6/Axl/Akt-mediated cell survival pathway, cell lysates extracted after six days were evaluated by a SDS-PAGE/Western blot analysis and representative results are shown. To compare each group, the expression level was presented as the relative value to the control without Pi treatment. The statistical analysis was performed on the results of three independent experiments. Pravastatin (50 µM) and olmesartan (100 µM) each partially inhibited the Pi-induced apoptosis and Ca deposition (upper panel), and restored the expression of Gas6, Axl and phosphorylated Akt (p-Akt) (lower panel). Combined treatment demonstrated not only additive inhibitory effects on apoptosis and the subsequent Ca deposition, but also additive restoration of this survival pathway.

*: $p < 0.05$ vs. Pi stimulation without drug treatment. #: $p < 0.05$ vs. Pi stimulation plus combined treatment.

effects²⁴⁻²⁶), and also the efficacy of statin administration²⁷. These findings strongly support our current findings. Notably, significant inhibition of aortic calcification was found in the pravastatin-treated rats, even at the lowest dose (1 mg/kg/day), which did not affect the renal function, lipid parameters or BP, suggesting that statins can attenuate aortic calcification through their direct vasoprotective effects. In addition, pravastatin at the middle dose (10 mg/kg/day) reduced the aortic Ca content more effectively than olmesartan (1 mg/kg/day), although the decline in the BP and the renal protection induced by pravastatin at that dose were smaller than those induced by olmesartan. This result implies that the inhibitory effects of pravastatin on aortic calcification are associated with its pleiotropic effects.

It has been shown that hypertension and hypercholesterolemia, accompanied by renal failure, augment the levels of several inflammatory cytokines, and statins exert an anti-inflammatory response associated with direct vasoprotection²⁸⁻³⁰. Based on these findings, the beneficial inhibitory effects of statins on the aortic calcification in cases of renal failure may, at least in part, result from their unique pleiotropic effects, including direct renoprotective and vasoprotective actions.

Inhibitory Effects of the ARB

We demonstrated dose-dependent effects of olmesartan on the inhibition of aortic calcification. In this study, the effects of the ARB beyond BP-lowering were not clear from the present data, because a significant reduction in the BP by olmesartan was observed even at the lowest dose (1 mg/kg/day). The severe renal dysfunction and subsequent hypertension were significantly improved by olmesartan; however, hypercholesterolemia was not. It is possible that the inhibitory effects of olmesartan on aortic calcification are in part attributable to its direct BP-lowering and renoprotective effects, which are independent of its effects on cholesterol. Strong renoprotection by ARBs, but not other antihypertensive drugs, via a reduction in proteinuria is well known, in addition to direct BP-lowering effects^{31, 32}. In addition, several reports have shown that ARBs improve the arterial stiffness, as assessed by the pulse wave velocity^{33, 34}. Especially in CKD patients, superior preventive effects for olmesartan on nocturnal hypertension and proteinuria have been suggested compared to other ARBs^{35, 36}. Furthermore, the detailed medical prescription³⁷ or combined use of olmesartan with other medications³⁸ was also recently suggested. The underlying benefits of ARB treatment may also be attributable to direct vaso-

protection independent of the effects on the BP. Therefore, our data suggest that ARBs, or at least olmesartan, may be beneficial for the prevention of aortic calcification in CKD.

Benefits of Combination Therapy

We explored the effects of combined administration of a statin and an ARB in our renal failure model. A significant decline in the BP and potent renal protection, with improvement of hyperphosphatemia, were observed in both the lowest-dose olmesartan group and the combination group. Although the lowest dose of pravastatin showed no significant effect on the laboratory parameters and BP, the combined use of olmesartan with pravastatin even at the lowest doses showed more effective inhibitory effects on aortic calcification not only in the histological assessment, but also in the quantitative assessment of the aortic Ca and P content, suggesting the increased benefit from the combined use from an early phase. Our results showing an additive improvement of the renal function and BP by the combination treatment are supported by some clinical and experimental reports^{39, 40}. One report revealed an additive benefit of the combination via an improvement of the endothelial function (as assessed by flow-mediated dilation) and a reduction of inflammatory markers (as assessed by the plasma monocyte chemoattractant protein-1 and malondialdehyde levels) in hypertensive, hypercholesterolemic patients³⁹. In addition, it has also been reported that combined treatment was superior to single treatment for inhibiting neointimal formation in rats with insulin resistance⁴¹. These findings strongly support our results showing the usefulness of combination therapy. It is well known that both statins and ARBs exert multiple effects, including organ protection, via their anti-oxidative and other pleiotropic actions⁴²⁻⁴⁴. Therefore, additional benefits of the combination therapy might contribute to the marked prevention of aortic calcification, together with stable hemodynamics, and provide a new therapeutic strategy for the management of aortic calcification in CKD.

Synergistic Protection from Apoptosis-based SMC Calcification by Combination Therapy

Hyperphosphatemia has been shown to be associated with vascular calcification in severe CKD⁴⁵. In fact, pravastatin and olmesartan partially improved the hyperphosphatemia in the renal failure rats, presumably via renal protection. We have previously reported that Pi-induced VSMC apoptosis played an essential role in vascular calcification¹⁰. In our animal experi-

ments, there was remarkable induction of apoptosis in the aortic wall found in the renal failure rats. The apoptosis was completely ameliorated by the combination treatment in the present study. In addition, the direct effects of these drugs on VSMC calcification in an *in vitro* model were evaluated. The Pi-induced apoptosis and subsequent calcification were partially inhibited by each drug alone, and significant synergistic inhibition was found with combined treatment. The protective effects of each drug were associated with the restoration of the Gas6/Axl survival pathway and its signaling, and the anti-apoptotic function was augmented by the combined treatment.

However, this manuscript is associated with one limitation, namely we were unable to detect Gas6 expression in the rat aorta. However, we confirmed that this pathway is crucial using a VSMC *in vitro* model for the inhibitory effects of both drugs. Our previous data showed that the expression of thrombomodulin, one of upstream molecules regulating Gas6-mediated apoptosis, was upregulated in the calcified aortas from the same rat model⁴⁶⁾, therefore, we believe that Gas6 was downregulated in the calcified aortas from rats. Although these additive benefits of combination therapy observed in our culture model strongly support the results from our animal experiments, the causal role of Gas6-related apoptosis in our rat model of vascular calcification needs to be confirmed in future studies.

Conclusion

We herein demonstrated that a statin and an ARB could each exert beneficial inhibitory effects on renal failure-induced aortic calcification not only due to their renoprotective effects, but also by their pleiotropic effects. Combined administration of pravastatin with olmesartan was superior to single-drug treatment for attenuating the vascular calcification. Our present work suggests that combination therapy with a statin and an ARB may thus be recommended as a new therapeutic strategy against vascular calcification in CKD patients.

Acknowledgements

This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (No. 19590854, No. 20249041 and No. 21590947), the Ono Medical Research Foundation, the Kanzawa Medical Research Foundation, the Novartis Foundation for Gerontological Research, the Takeda Research Foundation and

Mitsui-Sumitomo Insurance Welfare Foundation. The studies were also supported by Daiichi Sankyo Co., Ltd.

Conflicts of Interest

M.A. and Y.O. received lecture fees and research funding from Daiichi Sankyo Co., Ltd. The other authors declare that they have no financial interests regarding this study.

References

- 1) Abedin M, Tintut Y, Demer LL: Vascular calcification: mechanisms and clinical ramifications. *Arterioscler Thromb Vasc Biol*, 2004; 24: 1161-1170
- 2) Lehto S, Niskanen L, Suhonen M, Ronnema T, Laakso M: Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. *Arterioscler Thromb Vasc Biol*, 1996; 16: 978-983
- 3) Dao HH, Essalihi R, Bouvet C, Moreau P: Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. *Cardiovasc Res*, 2005; 66: 307-317
- 4) Cozzolino M, Dusso AS, Slatopolsky E: Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. *J Am Soc Nephrol*, 2001; 12: 2511-2516
- 5) Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. *Nephrol Dial Transplant*, 2000; 15: 218-223
- 6) Giachelli CM: Ectopic calcification: gathering hard facts about soft tissue mineralization. *Am J Pathol*, 1999; 154: 671-675
- 7) Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME: Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. *Circulation*, 1999; 100: 2168-2176
- 8) Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM: Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. *Arterioscler Thromb Vasc Biol*, 2003; 23: 489-494
- 9) Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Mori H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. *Circ Res*, 2000; 87: E10-17
- 10) Davignon J: Beneficial cardiovascular pleiotropic effects of statins. *Circulation*, 2004; 109: III39-43
- 11) Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T: Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. *J Am Soc Nephrol*, 2005; 16: 3631-3641

- 12) Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*, 2003; 361: 1149-1158
- 13) Son BK, Kozaki K, Iijima K, Eto M, Kojima T, Ota H, Senda Y, Maemura K, Nakano T, Akishita M, Ouchi Y: Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. *Circ Res*, 2006; 98: 1024-1031
- 14) Yokozawa T, Zheng PD, Oura H, Koizumi F: Animal model of adenine-induced chronic renal failure in rats. *Nephron*, 1986; 44: 230-234
- 15) Ikizler TA: Epidemiology of vascular disease in renal failure. *Blood Purif*, 2002; 20: 6-10
- 16) Johnson RC, Leopold JA, Loscalzo J: Vascular calcification: pathobiological mechanisms and clinical implications. *Circ Res*, 2006; 99: 1044-1059
- 17) Toussaint ND, Kerr PG: Vascular calcification and arterial stiffness in chronic kidney disease: Implications and management. *Nephrology*, 2007; 12: 500-509
- 18) Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD: HMG CoA reductase inhibitor (statin) and aortic valve calcium. *Lancet*, 2002; 359: 1125-1126
- 19) Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP: Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. *Circulation*, 2001; 104: 2205-2209
- 20) Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. *N Engl J Med*, 1998; 339: 1972-1978
- 21) Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A, Menendez T, Maeffert R, Kusus M, Regenfus M, Bickel A, Haberl R, Steinbeck G, Moshage W, Daniel WG: Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. *Circulation*, 2002; 106: 1077-1082
- 22) Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. *N Engl J Med*, 2005; 352: 2389-2397
- 23) Takenaka T, Takane H, Kikuta T, Watanabe Y, Suzuki H: Statin improves flow-mediated vasodilation in chronic kidney diseases. *Int J Hypertens*, 2013; 2013: 876865
- 24) Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. *Kidney Int*, 2001; 59: 260-269
- 25) Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC; Cholesterol and Recurrent Events Trial Investigators: CARE trial investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. *J Am Soc Nephrol*, 2003; 14: 1605-1613
- 26) Kasahara M, Nakagawa T, Yokoi H, Kuwabara T, Yasuno S, Mori K, Mukoyama M, Ueshima K: Do statins play a role in renoprotection? *Clin Exp Nephrol*, 2014 [Epub ahead of print]
- 27) Suzuki H, Watanabe Y, Kumagai H, Shuto H: Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. *Ther Adv Cardiovasc Dis*, 2013; 7: 306-315
- 28) Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF: Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. *Am J Cardiol*, 2005; 96: 1290-1292
- 29) Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB: Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. *Am J Kidney Dis*, 2002; 39: 1213-1217
- 30) Koh KK: Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. *Cardiovasc Res*, 2000; 47: 648-657
- 31) Izuwara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T: Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. *J Am Soc Nephrol*, 2005; 16: 3631-3641
- 32) Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, Shin MS, Ahn TH, Choi IS, Shin EK: Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. *J Am Coll Cardiol*, 2003; 42: 905-910
- 33) Karalliedde J, Smith A, DeAngelis L, Mirenda V, Kandra A, Botha J, Ferber P, Viberti G: Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. *Hypertension*, 2008; 51: 1617-1623
- 34) Agata J, Nagahara D, Kinoshita S, Takagawa Y, Moniwa N, Yoshida D, Ura N, Shimamoto K: Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension. *Circ J*, 2004; 68: 1194-1198
- 35) Ono T, Sanai T, Miyahara Y, Noda R: Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy. *Curr Ther Res Clin Exp*, 2013; 74: 62-67
- 36) Yanagi M, Tamura K, Fujikawa T, Wakui H, Kanaoka T, Ohsawa M, Azushima K, Maeda A, Kobori H, Umemura S: The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. *Hypertens Res*, 2013; 36: 262-269
- 37) Sakai Y, Suzuki A, Mugishima K, Sumi Y, Otsuka Y, Otsuka T, Ohno D, Murasawa T, Tsuruoka S: Comparison of once daily versus twice daily olmesartan in patients with chronic kidney disease. *Int J Nephrol Renovasc Dis*, 2013; 6: 223-227
- 38) Moriyama T, Tsuruta Y, Kojima C, Itabashi M, Sugiura H, Takei T, Ogawa T, Uchida K, Tsuchiya K, Nitta K: Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with

- chronic kidney disease. *Int Urol Nephrol*, 2012; 44: 841-845
- 39) Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. *Circulation*, 2004; 110: 3687-3692
- 40) Rodriguez-Iturbe B, Sato T, Quiroz Y, Vaziri ND: AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat. *Kidney Int*, 2004; 66: 668-675
- 41) Chen M, Ichiki T, Ohtsubo H, Imayama I, Inanaga K, Miyazaki R, Sunagawa K: Inhibition of balloon injury-induced neointimal formation by olmesartan and pravastatin in rats with insulin resistance. *Hypertens Res*, 2007; 30: 971-978
- 42) Koh KK, Cardillo C, Bui MN, Hathaway L, Csako G, Waclawiw MA, Panza JA, Cannon RO 3rd: Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. *Circulation*, 1999; 99: 354-360
- 43) Schiffrin EL, Park JB, Intengan HD, Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. *Circulation*, 2000; 101: 1653-1659
- 44) Wassmann S, Hilgers S, Laufs U, Böhm M, Nickenig G: Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. *Arterioscler Thromb Vasc Biol*, 2002; 22: 1208-1212
- 45) Coladonato JA: Control of hyperphosphatemia among patients with ESRD. *J Am Soc Nephrol*, 2005; 16: S107-114
- 46) Son BK, Akishita M, Iijima K, Ogawa S, Arai T, Ishii H, Maemura K, Aburatani H, Eto M, Ouchi Y: Thrombomodulin, a novel molecule regulating inorganic phosphate-induced vascular smooth muscle cell calcification. *J Mol Cell Cardiol*, 2013; 56: 72-80